Regeneron Pharmaceuticals reports $14.34 billion revenue for fiscal year ended December 31, 2025, up 1%
Regeneron Pharmaceuticals reported revenue of $14.34 billion for the year ended December 31, 2025, an increase of 1% from the previous year ($14.2 billion).
For the same period it posted net income of $4.5 billion, up 2.1%, or $41.48 per diluted share (38.34 a year earlier).
That is a net margin of 31.4%.
On Sanad's AAOIFI Standard 21 screen, Regeneron Pharmaceuticals is currently questionable: interest-bearing debt is 2.7% of market capitalisation (limit 30%), and impure income is 4.4% of revenue (limit 5%).
Is Regeneron Pharmaceuticals halal?
See the full AAOIFI screening of Regeneron Pharmaceuticals
See the full AAOIFI screening of Regeneron Pharmaceuticals
Source: 10-K filed with the U.S. Securities and Exchange Commission on February 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.